Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.62 |
| ▸ | HRH1 | P35367 | 3/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.62 |
| ▸ | HRH2 | P25021 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR1E | P28566 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38652842 | 0.91 | ABHD6 (0.62) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL3873145 | 0.91 | ABHD6 (0.65) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL31070584 | 0.90 | ABHD6 (0.64) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL3878092 | 0.89 | ABHD6 (0.68) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL2809581 | 0.87 | ABHD6 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL31070494 | 0.86 | HDAC1 (0.54) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL3876461 | 0.85 | ABHD6 (0.53) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL14959461 | 0.85 | TMEM97 (0.66) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL3880350 | 0.84 | HDAC1 (0.52) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL12187763 | 0.83 | TMEM97 (0.74) | TMEM97SIGMAR1HRH1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-09-09 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | TMEM97 568/4885SIGMAR1 58/4885HRH1 76/4885 |
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | ABHD6, FAAH, FAAH2 | TMEM97 821/4885SIGMAR1 1648/4885HRH1 59/4885 |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | TMEM97 579/4885SIGMAR1 1416/4885HRH1 427/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | TMEM97 2415/4885SIGMAR1 861/4885HRH1 3209/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | TMEM97 821/4885SIGMAR1 1648/4885HRH1 59/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | TMEM97 550/4885SIGMAR1 57/4885HRH1 76/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | TMEM97 2014/4885SIGMAR1 4365/4885HRH1 1711/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | TMEM97 579/4885SIGMAR1 1416/4885HRH1 427/4885 |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | TMEM97 579/4885SIGMAR1 1416/4885HRH1 427/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | TMEM97 579/4885SIGMAR1 1416/4885HRH1 427/4885 |
| US-20210277007-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | TMEM97 579/4885SIGMAR1 1416/4885HRH1 427/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | TMEM97 2014/4885SIGMAR1 4365/4885HRH1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.